Zhiwei Zheng, Huide Zhu, Ling Fang. "Tislelizumab plus chemotherapy versus chemotherapy as first-line treatment for extensive-stage small cell lung cancer: A cost-effectiveness analysis." PLoS ONE (2025). https://doi.org/10.1371/journal.pone.0320189